Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632.

Antimicrobial agents and chemotherapy - 1 Sept 2000

Gong Y F, Robinson B S, Rose R E, Deminie C, Spicer T P, Stock D, Colonno R J, Lin P F

Abstract excerpt

BMS-232632 is an azapeptide human immunodeficiency virus (HIV) type 1 (HIV-1) protease inhibitor that displays potent anti-HIV-1 activity (50% effective concentration [EC(50)], 2.6 to 5.3 nM; EC(90), 9 to 15 nM). In vitro passage of HIV-1 RF in the presence of inhibitors showed that BMS-232632 selected for resistant variants more slowly than nelfinavir or ritonavir did. Genotypic and phenotypic analysis of three...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Microbial
Share to Drug Resistance, Multiple

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to HIV Protease

Share to HIV Protease Inhibitors

Share to Oligopeptides

Share to Pyridines

Share to Substrate Specificity

Source

Open in PubMed Open full text

Identifiers

PMID: 10952574
DOI: 10.1128/AAC.44.9.2319-2326.2000
PMCID: PMC90064

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632.PMID 10952574Read ↗

Resistance of human immunodeficiency virus type 1 to protease inhibitors: selection of resistance mutations in the presence and absence of the drug.Semantic proximity Read ↗

Characterization of a human immunodeficiency virus type 1 variant with reduced sensitivity to an aminodiol protease inhibitor.Semantic proximity Read ↗

Activities of atazanavir (BMS-232632) against a large panel of human immunodeficiency virus type 1 clinical isolates resistant to one or more approved protease inhibitors.Semantic proximity Read ↗

In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor.Semantic proximity Read ↗

TMC310911, a novel human immunodeficiency virus type 1 protease inhibitor, shows in vitro an improved resistance profile and higher genetic barrier to resistance compared with current protease inhibitors.Semantic proximity Read ↗

Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors.Semantic proximity Read ↗

Protease inhibitors: resistance, resistance, resistance.Semantic proximity Read ↗

In vitro cross-resistance profile of nucleoside reverse transcriptase inhibitor (NRTI) BMS-986001 against known NRTI resistance mutations.Semantic proximity Read ↗

HIV-1 protease mutations and protease inhibitor cross-resistance.Semantic proximity Read ↗

In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1.Semantic proximity Read ↗

Selection of high-level resistance to human immunodeficiency virus type 1 protease inhibitors.Semantic proximity Read ↗

In-vitro phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitor S/GSK1349572.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.